Results 141 to 150 of about 57,561 (211)

Case Report: Fulminant Pediatric Vascular Behçet Disease Presenting With Budd-Chiari Syndrome and Extensive Multivessel Venous Thrombosis. [PDF]

Int J Rheum Dis
Karadoğan MT, Akyel NG, Tekgündüz SA, Şevketoğlu E, Çakmak F.   +4 more
europepmc   +1 more source

Assessment of Hypercoagulability After Orthopedic Trauma Surgery Using Coagulation Biomarkers and TEG/ROTEM. [PDF]

Int J Mol Sci
Huzum B, Cionca DV, Ciupilan D, Tesoi DF, Mircea C, Badulescu OV.   +5 more
europepmc   +1 more source

Fibrin-bound thrombin determines clot structure and blood thrombogenicity in normofibrinogenemia and dysfibrinogenemia. [PDF]

Haematologica
Sun S, Roest M, Urbanus RT, Campello E, Beck S, Bulato C, Connell SD, De Groot PG, Feller T, Huskens D, Konings J, Marchi R, Middelveld H, Oftering P, Nieswandt B, Casini A, Ariens RAS, Simioni P, Heemskerk JWM, De Laat B.   +19 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The genetics of antithrombin

Thrombosis Research, 2018
Antithrombin is a key endogenous anticoagulant whose deficiency constitutes a strong risk factor for thrombosis. The study of antithrombin deficiency has generated excellent, and in some cases, surprising results that may be extrapolated to other ...
María Eugenia de la Morena Barrio, Vicente Vicente, Javier Corral   +2 more
exaly   +4 more sources

Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency

Thrombosis and Haemostasis, 2009
SummaryAntithrombin (AT) functions as a potent natural anticoagulant and serine protease inhibitor that inactivates many enzymes in the coagulation cascade. Antithrombin also possesses anti-inflammatory properties, many of which are mediated by its actions as an anticoagulant.
George M Rodgers
exaly   +3 more sources

A Randomized Controlled Trial of Antithrombin Supplementation During Extracorporeal Membrane Oxygenation

Critical Care Medicine, 2020
Supplemental Digital Content is available in the text. Objectives: Supplementation of antithrombin might decrease the amount of heparin needed to achieve a given anticoagulation target during extracorporeal membrane oxygenation.
M. Panigada, Alberto Cucino, E. Spinelli, G. Occhipinti, G. Panarello, C. Novembrino, D. Consonni, A. Protti, A. Lissoni, A. Arcadipane, A. Pesenti, G. Grasselli   +11 more
semanticscholar   +1 more source

Antithrombin III microheterogeneity in antithrombin III deficiency and in the antithrombin III abnormality, “antithrombin III toyama”

Thrombosis Research, 1987
Antithrombin III (AT III) microheterogeneity was investigated in 12 cases of congenital AT III deficiency and 2 cases of congenital AT III abnormality by isoelectric focusing (IEF) and immunofixation. In congenital AT III deficiency, IEF and immunofixation revealed AT III as 8 bands which was indistinguishable from normal control in terms of the number
N, Sakuragawa, S, Kondo, M, Katoh, K, Takahashi, T, Koide   +4 more
openaire   +2 more sources

Antithrombin and heparin

Molecular Medicine Today, 1995
Antithrombin, the main inhibitor of thrombosis in blood, is bound and activated by the heparin-like side-chains that line the small vasculature. We now have good depictions of the heparin-binding site on antithrombin, and of the way in which mutations at this site cause thrombotic disease.
R, Carrell, R, Skinner, M, Warden, J, Whisstock   +3 more
openaire   +2 more sources